drugset
drugset / Trial / NCT01221818

A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects

NCT01221818 ↗

Phase 1 Completed 48 enrolled Eisai Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of single oral ascending doses of E6007 in healthy subjects.

Timeline

Start
2010-09
Primary completion
2011-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject E6007 Unknown 25 mg Oral
Subject E6007 Unknown 50 mg Oral
Subject E6007 Unknown 100 mg Oral
Subject E6007 Unknown 200 mg Oral
Subject E6007 Unknown 400 mg Oral
Subject E6007 Unknown 600 mg Oral

Indications

inflammatory bowel disease